HLN Stock Analysis: Haleon | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 43.333m USD | 12M Return: 1.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 86.0M
EPS Trend: -2.8%
Qual. Beats: 0
Rev. Trend: 83.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 3.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Haleon plc (NYSE: HLN) is a global consumer healthcare company headquartered in Weybridge, United Kingdom, with origins dating back to 1715. The company researches, develops, manufactures, and sells a broad portfolio of over-the-counter (OTC) health products across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. Its offering spans oral health (Sensodyne, Polident, Parodontax, Biotene), vitamins and supplements (Centrum, Emergen-C, Caltrate), respiratory relief (Theraflu, Flonase), pain management (Voltaren, Panadol, Advil), and digestive and allergy products (TUMS, ENO, Fenistil).
The firm was spun off from GlaxoSmithKline and listed on the NYSE in July 2022, originally incorporated as DRVW 2022 plc before adopting the Haleon name. As a pure-play consumer healthcare business, Haleon competes in the global OTC and personal care segment, which is generally characterized by brand-led, consumer-marketed products sold through retail pharmacies, grocery, and e-commerce channels rather than through prescription-based distribution models typical of the broader healthcare industry.
- Sensodyne oral health pricing power drives segment revenue growth
- Post-spin-off debt paydown pace limits buyback and dividend flexibility
- Strong pound translation headwind pressures reported revenue and margin
| Net Income: 2.78b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.07 > 1.0 |
| NWC/Revenue: -1.98% < 20% (prev -0.55%; Δ -1.43% < -1%) |
| CFO/TA 0.17 > 3% & CFO 5.43b > Net Income 2.78b |
| Net Debt (7.40b) to EBITDA (4.76b): 1.56 < 3 |
| Current Ratio: 0.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.48b) vs 12m ago -1.77% < -2% |
| Gross Margin: 63.76% > 18% (prev 61.43%; Δ 2.33% > 0.5%) |
| Asset Turnover: 57.63% > 50% (prev 49.42%; Δ 8.22% > 0%) |
| Interest Coverage Ratio: 7.61 > 6 (EBIT TTM 4.24b / Interest Expense TTM 557.5m) |
| A: -0.01 (Total Current Assets 4.54b - Total Current Liabilities 4.92b) / Total Assets 32.6b |
| B: 0.50 (Retained Earnings 16.1b / Total Assets 32.6b) |
| C: 0.13 (EBIT TTM 4.24b / Avg Total Assets 33.4b) |
| D: 1.02 (Book Value of Equity 16.4b / Total Liabilities 16.1b) |
| Altman-Z'' = 3.46 = A |
| DSRI: 0.98 (Receivables 2.12b/1.90b, Revenue 19.3b/17.0b) |
| GMI: 0.96 (GM 61.43% / 63.76%) |
| AQI: 1.03 (AQ_t 0.80 / AQ_t-1 0.78) |
| SGI: 1.14 (Revenue 19.3b / 17.0b) |
| TATA: -0.08 (NI 2.78b - CFO 5.43b) / TA 32.6b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at USD 9.86 with a total of 6,312,922 shares traded. Over the past week, the price has changed by +1.44%, over one month by +8.71%, over three months by +0.31% and over the past year by +1.53%.
Current recommended Stop Loss: 9.40 (which is 4.7% or 2.7 ATR below the current price).
Haleon has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy HLN.
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 11.7 | 18.2% |
Market Cap GBP = 32.4b (43.3b USD * 0.7474 USD.GBP)
P/E Trailing = 20.0816
P/E Forward = 18.5874
P/S = 3.9287
P/B = 1.9945
P/EG = 2.6193
Revenue TTM = 19.3b GBP
EBIT TTM = 4.24b GBP
EBITDA TTM = 4.76b GBP
Long Term Debt = 7.66b GBP (from longTermDebt, last quarter)
Short Term Debt = 882.5m GBP (from shortTermDebt, last quarter)
Debt = 8.73b GBP (from shortLongTermDebtTotal, last quarter) + Leases 133.0m
Net Debt = 7.40b GBP (calculated: Debt 8.73b - CCE 1.32b)
Enterprise Value = 39.8b GBP (32.4b + Debt 8.73b - CCE 1.32b)
Interest Coverage Ratio = 7.61 (Ebit TTM 4.24b / Interest Expense TTM 557.5m)
EV/FCF = 20.19x (Enterprise Value 39.8b / FCF TTM 1.97b)
FCF Yield = 4.95% (FCF TTM 1.97b / Enterprise Value 39.8b)
FCF Margin = 10.22% (FCF TTM 1.97b / Revenue TTM 19.3b)
Net Margin = 14.43% (Net Income TTM 2.78b / Revenue TTM 19.3b)
Gross Margin = 63.76% ((Revenue TTM 19.3b - Cost of Revenue TTM 6.99b) / Revenue TTM)
Gross Margin QoQ = 65.03% (prev 64.51%)
Tobins Q-Ratio = 1.22 (Enterprise Value 39.8b / Total Assets 32.6b)
Interest Expense / Debt = 6.39% (Interest Expense 557.5m / Debt 8.73b)
Taxrate = 22.09% (794.7m / 3.60b)
NOPAT = 3.31b (EBIT 4.24b * (1 - 22.09%))
Current Ratio = 0.92 (Total Current Assets 4.54b / Total Current Liabilities 4.92b)
Debt / Equity = 0.53 (Debt 8.73b / totalStockholderEquity, last quarter 16.4b)
Debt / EBITDA = 1.56 (Net Debt 7.40b / EBITDA 4.76b)
Debt / FCF = 3.76 (Net Debt 7.40b / FCF TTM 1.97b)
Total Stockholder Equity = 16.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.31% (Net Income 2.78b / Total Assets 32.6b)
RoE = 17.26% (Net Income TTM 2.78b / Total Stockholder Equity 16.1b)
RoCE = 17.85% (EBIT 4.24b / Capital Employed (Equity 16.1b + L.T.Debt 7.66b))
RoIC = 11.99% (NOPAT 3.31b / Invested Capital 27.6b)
WACC = 5.02% (E(32.4b)/V(41.1b) * Re(5.03%) + D(8.73b)/V(41.1b) * Rd(6.39%) * (1-Tc(0.22)))
Discount Rate = 5.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -88.93 | Cagr: -1.45%
[DCF] Terminal Value 74.90% ; FCFF base≈2.00b ; Y1≈1.95b ; Y5≈1.93b
[DCF] Fair Price = 5.18 (EV 30.2b - Net Debt 7.40b = Equity 22.8b / Shares 4.40b; r=8.35% [WACC [floored]]; 5y FCF grow -3.91% → 2.50% )
EPS Correlation: -2.77 | EPS CAGR: -4.90% | SUE: -0.22 | # QB: 0
Revenue Correlation: 83.37 | Revenue CAGR: 17.07% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=0.55 | Chg30d=-1.77% | Revisions=-40% | GrowthEPS=+8.2% | GrowthRev=+3.4%
EPS next Year (2027-12-31): EPS=0.61 | Chg30d=-0.82% | Revisions=-40% | GrowthEPS=+10.4% | GrowthRev=+4.3%
[Analyst] Revisions Ratio: -57% (up=0, down=4)